Blood protein concentrations in PRIORITY prior to randomization

The Early Detection of Diabetic Kidney Disease by Urinary Proteomics and
Subsequent Intervention with Spironolactone to Delay Progression (PRIORITY)
study was a multicentre, prospective, observational study with embedded
randomised controlled trial, which recruited people with type 2 diabetes, normal
urinary albumin excretion, and preserved renal function. All participants
(observational cohort) were tested with the CKD273 classifier and classified as high
risk (CKD273 classifier score >0·154) or low risk (≤0·154). Participants, who were
classified as high risk were entered into a randomised controlled trial and randomly
assigned (1:1) by use of an interactive web-response system, to receive
spironolactone 25 mg once daily or matched placebo (trial cohort). 
The DC-ren project selected 79 patients from this cohort for in-depth molecular
characterization for baseline measurements of blood and urinary biomarker
candidates.

The here described data set comprises blood protein concentrations
determined by Luminex. Data from a total 79 study visits are available.